Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Polarean notes statement from Amphion Innovations

10 Sep 2019 17:15

RNS Number : 8812L
Polarean Imaging PLC
10 September 2019
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Polarean notes statement from Amphion Innovations

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that 1,150,000 shares in Polarean have been sold for partial repayment of Amphion's loan facility which was originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.

Following this sale, Amphion holds 17,122,523 ordinary shares of Polarean, representing 14.96% of the Company's issued share capital.

The full TR-1 disclosure is set out below.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

     

 

 

 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Polarean Imaging plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Amphion Innovations plc

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

September 6 2019

6. Date on which issuer notified (DD/MM/YYYY):

September 9 2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.96%

 

 

114,438,600

Position of previous notification (if

applicable)

15.97%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB008BVVT4H71

17,122,523

 

14.96%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

17,122,523

14.96%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

London, UK

Date of completion

September 6 2019

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKNEFFDNEFF
Date   Source Headline
23rd Dec 20257:00 amRNSCancellation - Polarean Imaging Plc
15th Dec 20254:03 pmRNSResult of General Meeting
1st Dec 20257:00 amRNSChest coil passes Philips compatibility testing
25th Nov 20257:00 amRNSFirst Xenon Hyperpolariser in Asia
24th Nov 20257:00 amRNSKorean distributor agreement with DK Healthcare
14th Nov 20257:00 amRNSProposed Cancellation of Admission & Notice of GM
27th Oct 20253:37 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSStrategic review and consideration of AIM listing
6th Oct 20257:00 amRNSAscend Imaging agreement expansion
29th Sep 20257:00 amRNSUniversity of Virginia Health Hospital agreement
25th Sep 202512:14 pmRNSNational Institutes of Health system order
25th Sep 20257:00 amRNSHalf-year Report
16th Sep 20257:00 amRNSNotice of Results
11th Sep 20254:36 pmRNSHolding(s) in Company
12th Aug 20257:00 amRNSSubmission of new Phase III study protocol to FDA
24th Jul 20257:00 amRNSBlock Listing Six Monthly Return
24th Jun 20257:00 amRNSPromotion & sales representative agreement
9th Jun 20254:16 pmRNSResult of AGM
2nd Jun 20257:00 amRNSFDA expands XENOVIEW indication
21st May 20257:00 amRNSDr. Bastiaan Driehuys awarded by ATS
15th May 202512:48 pmRNSXenon MRI featured prominently at ATS 2025
14th May 20252:25 pmRNSOngoing collaboration with Philips
8th May 20257:00 amRNSFinal Results
6th May 20252:59 pmRNSHolding(s) in Company
25th Apr 20257:00 amRNSNotice of Results
10th Mar 20257:00 amRNSExpansion of Xenon MRI imaging platform
27th Feb 20257:00 amRNSFY24 trading update
19th Feb 20257:00 amRNSVirtual Investor Day
3rd Feb 20257:00 amRNSTaiwanese distributor agreement with Sumtage
30th Jan 20257:00 amRNSKey patent in China secured
28th Jan 20257:00 amRNSCollaboration to Advance Lung Imaging Innovation
24th Jan 20257:00 amRNSBlock Listing Six Monthly Return
11th Dec 20242:52 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSFDA clears Chest Coil in GE HealthCare MRI Systems
25th Sep 20247:00 amRNSVirtual investor day
4th Sep 20247:00 amRNSHalf-year Report
3rd Sep 20247:00 amRNSAppointment of Vice President of Sales
28th Aug 20247:00 amRNSAppointment of Chief Medical Advisor
21st Aug 20247:00 amRNSNotice of Results
15th Aug 20247:00 amRNSAppointment of Bastiaan Driehuys as consultant
1st Aug 20247:00 amRNSFDA submission to expand minimum age for XENOVIEW™
31st Jul 20247:00 amRNSNew Xenon MRI System trade-in agreement
29th Jul 20247:00 amRNSRepricing of Options and Grant of Options
26th Jul 20247:00 amRNSBlock Listing Six Monthly Return
24th Jul 20242:36 pmRNSResult of AGM
19th Jul 202410:36 amRNSXenon MRI System trade-in agreement
18th Jul 20245:33 pmRNSPDMR Dealing
28th Jun 20247:00 amRNSFinal Results
19th Jun 20245:23 pmRNSHolding(s) in Company
19th Jun 20245:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.